Head-to-head evidence
Paliperidone palmitate (Invega Trinza) vs Ziprasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone palmitate (Invega Trinza)
Marketed by Johnson & Johnson
NCT02713282 · Phase 3 · completed
This was a single-group, open-label study without randomization or a comparator arm, so it could not directly compare the 3-month formulation with placebo or another treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Ziprasidone
Marketed by Pfizer and partners
NCT00159770 · Phase 3 · completed
The study used randomization and active comparators but was open-label, with 290 participants, and its primary clinical endpoint was PANSS symptom change. No results are posted, so the primary endpoint cannot be classified as met or missed.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone palmitate (Invega Trinza)'s landscape · Ziprasidone's landscape